isabelobrien, Author at European Medical Journal - Page 28 of 68

The changing face of field medical affairs

There are many pillars of medical affairs, but field teams are where the action happens. How do you build teams that deliver results?

Marc Hoffman

Hema Now: Episode 8: What’s Next in Lymphoma Diagnosis and Treatment?

Marc Hoffman, Associate Professor in Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discusses the future of lymphoma care.

Robeauté’s microbot brain technology secures $28m

The company’s microbot technology holds huge potential for exploring and delivering treatments to the brain.

Checklist

Major changes to product information leaflets to hit Europe

The European pharma sector is on the brink of regulatory and operational updates with new papers from pharmaceutical associations

Illustration of a heart with a monitor

Heart failure drug market to reach $33.7bn by 2032

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe and Japan.

Needle-free vaccine technology wins $3.7m in funding from CEPI

Micron Biomedical, an Atlanta-based life sciences company, has received funding for its technology that could improve vaccine access.

Ahmad Awada

Onc Now: Episode 8: New Frontiers in Oncology and Drug Development

Ahmad Awada, Head of the Oncology Department at Chirec Cancer Institute discusses groundbreaking developments in cancer care.

Handshake on blue background

Vertex strikes deal for Orna Therapeutics' LNP technology

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and beta-thalassemia.

Illustration of vaccine factory.

WuXi Biologics offloads Irish vaccine plant to Merck for $500m

WuXi Biologics sells its vaccine production facility in Ireland to Merck & Co for $500m in the wake of changing regulation in the US.

Gold crown on blue background

Could Eli Lilly take the crown in the obesity market?

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.